SNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sanofi SA (SNY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive catalysts like FDA approvals and hedge fund buying, the technical indicators are bearish, and recent analyst ratings and price target changes suggest limited upside in the near term. The absence of strong proprietary trading signals further supports a cautious approach.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 32.175, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 42.348, with resistance at 43.641.
FDA approval for expanded use of Tzield therapy and European Commission approval for Sarclisa in multiple myeloma patients. Hedge fund buying has increased by 231.75% over the last quarter.
Recent analyst downgrades from Morgan Stanley and BNP Paribas, citing limited near-term catalysts and pipeline concerns. Bearish technical indicators and lack of significant insider trading trends.
No financial data available for analysis.
Recent analyst ratings are mixed to negative. Deutsche Bank maintains a Buy rating but lowered the price target. Morgan Stanley and BNP Paribas downgraded the stock, citing limited catalysts and pipeline concerns.
